反応式
Br[C:2]1[N:7]=[C:6]([N:8]2[C:16]3[CH:15]=[C:14]([C:17]4[CH:22]=[N:21][CH:20]=[C:19]([CH3:23])[N:18]=4)[N:13]=[CH:12][C:11]=3[CH:10]=[N:9]2)[CH:5]=[CH:4][C:3]=1[O:24][CH3:25].[NH:26]1[CH2:31][CH2:30][CH2:29][NH:28][C:27]1=[O:32].C(=O)([O-])[O-].[K+].[K+].CNCCNC>[Cu]I>[CH3:25][O:24][C:3]1[C:2]([N:26]2[CH2:31][CH2:30][CH2:29][NH:28][C:27]2=[O:32])=[N:7][C:6]([N:8]2[C:16]3[CH:15]=[C:14]([C:17]4[CH:22]=[N:21][CH:20]=[C:19]([CH3:23])[N:18]=4)[N:13]=[CH:12][C:11]=3[CH:10]=[N:9]2)=[CH:5][CH:4]=1参加物
6
反応物 4
生成物 1
試薬・触媒・溶媒 1
反応条件
- 温度
- 110 °C
実験手順
A solution containing 1-(6-bromo-5-methoxy-2-pyridyl)-6-(6-methylpyrazin-2-yl)pyrazolo[4,3-c]pyridine (50 mg, 0.126 mmol), tetrahydro-2-pyrimidinone (40 mg, 0.38 mmol), Copper(I) iodide (126 mg, 0.126 mmol), Potassium carbonate (21 mg, 0.15 mmol) and N,N′-Dimethylethylenediamine (0.028 mL, 0.252 mmol) was stirred at 110° C. 18 h. The reaction was filtered through celite and concentrated. The crude product was submitted for reverse phase HPLC to give 251 (8 mg, 14%). MS (ESI) m/z: 417.1. 1H NMR (400 MHz, DMSO) δ 9.61 (s, 1H), 9.47 (s, 1H), 9.33 (s, 1H), 8.68 (s, 1H), 8.63 (s, 1H), 7.89 (d, J=8.7 Hz, 1H), 7.77 (d, J=8.8 Hz, 1H), 6.74 (s, 1H), 3.86 (s, 3H), 3.35 (d, J=5.4 Hz, 2H), 2.63 (s, 3H), 2.16-2.08 (m, 2H).
後処理
- custom18 h
- filtrationThe reaction was filtered through celite
- concentrationconcentrated
出典と根拠
- ORDレコード
- ord-ac7e2d53a6244edfa23396fb3a7afb42
- 出典データセット
- uspto-grants-2016_09
- 特許番号
- US09434725B2
関連ノート
読み込み中…